A method for preparing a pharmaceutically acceptable salt of 6-Azaindole according to the invention may be carried out by an appropriate combination of those methods that are conventionally used in the field of organic synthetic chemistry. A specific example thereof is a method in which a solution of the compound in its free form is subjected to neutralization titration with an alkaline solution or an acidic solution.
Examples of the ester of 6-Azaindole(CAS NO.: 271-29-4) include methyl ester and ethyl ester. Such esters can be prepared by esterification of a free carboxyl group according to a conventional method.
With regard to each preparation, various preparation forms can be selected, and examples thereof include oral preparations such as tablets, capsules, powders, granules or liquids, or sterilized liquid parenteral preparations such as solutions or suspensions, suppositories, ointments and the like.
Solid preparations of 6-Azaindole can be prepared in the forms of tablet, capsule, granule and powder without any additives, or prepared using appropriate carriers (additives). Examples of such carriers (additives) may include saccharides such as lactose or glucose; starch of corn, wheat or rice; fatty acids such as stearic acid; inorganic salts such as magnesium metasilicate aluminate or anhydrous calcium phosphate; synthetic polymers such as polyvinylpyrrolidone or polyalkylene glycol; alcohols such as stearyl alcohol or benzyl alcohol; synthetic cellulose derivatives such as methylcellulose, carboxymethylcellulose, ethylcellulose or hydroxypropylmethylcellulose; and other conventionally used additives such as gelatin, talc, plant oil and gum arabic.
These solid preparations such as tablets, capsules, granules and powders may generally contain, for example, 0.1 to 100% by weight, and preferably 5 to 98% by weight, of 6-Azaindole of the Formula I as an active ingredient, based on the total weight of the preparation.
Liquid preparations are produced in the forms of suspension, syrup, injection and drip infusion (intravenous fluid) using appropriate additives that are conventionally used in liquid preparations, such as water, alcohol or a plant-derived oil such as soybean oil, peanut oil and sesame oil.
In particular, when the preparation is administered parenterally in a form of intramuscular injection, intravenous injection or subcutaneous injection, appropriate solvent or diluent may be exemplified by distilled water for injection, an aqueous solution of lidocaine hydrochloride (for intramuscular injection), physiological saline, aqueous glucose solution, ethanol, polyethylene glycol, propylene glycol, liquid for intravenous injection (e.g., an aqueous solution of citric acid, sodium citrate and the like) or an electrolytic solution (for intravenous drip infusion and intravenous injection), or a mixed solution thereof.
Such injection may be in a form of a preliminarily dissolved solution, or in a form of powder per se or powder associated with a suitable carrier (additive) which is dissolved at the time of use. The injection liquid may contain, for example, 0.1 to 10% by weight of an active ingredient based on the total weight of the preparation.
Liquid preparations of 6-Azaindole such as suspension or syrup for oral administration may contain, for example, 0.1 to 10% by weight of an active ingredient based on the total weight of the preparation.
Each preparation can be prepared by a person having ordinary skill in the art according to conventional methods or common techniques. For example, a preparation containing another antitumor agent that is used in combination with the compound represented by the above Formula I, can be prepared, if the preparation is an oral preparation, for example, by mixing an appropriate amount of the antitumor agent with an appropriate amount of lactose and filling this mixture into hard gelatin capsules which are suitable for oral administration. On the other hand, preparation can be carried out, if the preparation containing the antitumor agent is an injection, for example, by mixing an appropriate amount of the antitumor agent with an appropriate amount of 0.9% physiological saline and filling this mixture in vials for injection.
Want to learn more information about 6-Azaindole, you can access the guidechem.com. Guidechem.com is just a place for you to look for some chemicals.
2013年9月29日星期日
2013年9月22日星期日
What is 6-Azaindole?
Chemical and physical properties
Product Name: 6-Azaindole
English Synonyms: 1H-Pyrrolo [2,3-c] pyridine, Harmyrine, 1,6-Diazaindene
CAS Number: 271-29-4
Molecular formula: C7H6N2
Molecular Weight: 118.14
Density: 1.242 g / cm3
Melting point: 136 - 137 ° c
Boiling Point: 295.761 ° c at 760 mmhg
Flash Point: 137.4 ° c
Appearance: 6-Azaindole is a kind of white powder.
Usage
6-Azaindole is a kind of important organic synthesis intermediates.
Safety information
Hazard Codes: Xi
Hazard Note: Irritant
HS CODE: 29339980
Related Categories
You may be interested in these following chemicals,you can access guidechem.com to get more information about 6-Azaindole or some other related chemicals.
Indole Series
Indole
Indoles and derivatives
Indole
Heterocyclic Compounds
Indole Series
Azaindole
Building Blocks
Azaindoles
Product Name: 6-Azaindole
English Synonyms: 1H-Pyrrolo [2,3-c] pyridine, Harmyrine, 1,6-Diazaindene
CAS Number: 271-29-4
Molecular formula: C7H6N2
Molecular Weight: 118.14
Density: 1.242 g / cm3
Melting point: 136 - 137 ° c
Boiling Point: 295.761 ° c at 760 mmhg
Flash Point: 137.4 ° c
Appearance: 6-Azaindole is a kind of white powder.
Usage
6-Azaindole is a kind of important organic synthesis intermediates.
Safety information
Hazard Codes: Xi
Hazard Note: Irritant
HS CODE: 29339980
Related Categories
You may be interested in these following chemicals,you can access guidechem.com to get more information about 6-Azaindole or some other related chemicals.
Indole Series
Indole
Indoles and derivatives
Indole
Heterocyclic Compounds
Indole Series
Azaindole
Building Blocks
Azaindoles
订阅:
博文 (Atom)

